Predictive models in external beam radiotherapy for clinically localized prostate cancer

Cancer

Volumn 115, Issue SUPPL 13, 2009, Pages 3112-3120

  Roach III, Mack ^a   Waldman, Fred ^a,b   Pollack, Alan ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Predictive models; Prostate cancer; Radiotherapy; Randomized trials

Indexed keywords

ADENINE; BIOLOGICAL MARKER; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 2; CYTOCHROME P450 3A4; CYTOSINE; DNA; GUANINE; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; STAT3 PROTEIN; TUMOR MARKER;

CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONFERENCE PAPER; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MODEL; NOMOGRAM; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RISK ASSESSMENT; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE III AS TOPIC; FORECASTING; HUMANS; MALE; MODELS, STATISTICAL; NOMOGRAMS; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 67649978936     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24348     Document Type: Conference Paper

References (39)

1. Khoo VS, Pollack A, Cowen D, et al. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate. 1999;41:166-172.
2. Stoyanova R, Hachem P, Hensley H, et al. Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo. Int J Radiat Oncol Biol Phys. 2007;68:1151-1160.
3. Pollack A, Grignon DJ, Heydon KH, et al. Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. J Clin Oncol. 2003;21:1238-1248.
4. Grignon DJ, Caplan R, Sarkar FH, et al. p53 Status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst. 1997;89:158-165.
5. Che M, DeSilvio M, Pollack A, et al. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. Int J Radiat Oncol Biol Phys. 2007;69:1117-1123.
6. Chakravarti A, Heydon K, Wu CL, et al. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10. J Clin Oncol. 2003;21:3328-3334.
7. Chakravarti A, DeSilvio M, Zhang M, et al. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. J Clin Oncol. 2007;25:3082-3089.
8. Li R, Heydon K, Hammond ME, et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in Radiation Therapy Oncology Group protocol 86-10. Clin Cancer Res. 2004;10(12 pt 1):4118-4124.
9. Pollack A, DeSilvio M, Khor LY, Li, et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol. 2004;22:2133-2140.
10. Khor LY, Desilvio M, Al-Saleem T, et al. MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer. 2005;104:962-967.
11. Khor LY, Desilvio M, Li R, et al. Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. Int J Radiat Oncol Biol Phys. 2006;66:25-30.
12. Khor LY, Moughan J, Al-Saleem T, et al. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on Radiation Therapy Oncology Group protocol 92-02. Clin Cancer Res. 2007;13:3585-3590.
13. Abdel-Wahab M, Berkey BA, Krishan A, et al. Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Am J Clin Oncol. 2006;29:14-20.
14. Khor LY, Bae K, Pollack A, et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol. 2007;8:912-920.
15. Torres-Roca JF, DeSilvio M, Mora LB, et al. Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10. Urology. 2007;69:505-509.
16. Roach M 3rd, De Silvio M, Rebbick T, et al. Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2007;69:79-87.
17. Khor LY, Bae K, Al-Saleem T, et al. Protein kinase A RIalpha predicts for prostate cancer outcome: analysis of Radiation Therapy Oncology Group Trial 86-10. Int J Radiat Oncol Biol Phys. 2008;71:1309-1315.
18. Ross PL, Gerigk C, Gonen M, et al. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol. 2002;20:82-88.
19. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of 3-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000;18:3352-3359.
20. Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, Bostwick DG. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer. 1997;79:337-344.
21. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
22. Zelefsky MJ, Lyass O, Fuks Z, et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and 3-dimensional conformal radiotherapy. J Clin Oncol. 1998;16:3380-3385.
23. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110-114.
24. Roach M 3rd. Re: the use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:1923-1924.
25. Roach M, Lu J, Pilepich MV, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 2000;47:609-615.
26. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate endpoint for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376-1383.
27. Roach M 3rd, Weinberg V, Nash M, Sandler HM, McLaughlin PW, Kattan MW. Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials. J Urol. 2006;176(6 pt 2):S16-S20.
28. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol. 2002;167:1681-1686.
29. Briganti A, Chun FK, Salonia A, et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int. 2006;98:788-793.
30. Briganti A, Karakiewicz PI, Chun FK, et al. Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. Eur Urol. 2007;51:1573-1581.
31. D'Amico AV, Renshaw AA, Cote K, et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol. 2004;22:3726-3732.
32. Roach M 3rd. Hormonal therapy and radiotherapy for localized prostate cancer: who, where and how long? J Urol. 2003;170:S35-S40; discussion S40-S41.
33. [No authors listed] Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997;37:1035-1041.
34. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965-974.
35. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram that predicts 5-year probability of metastasis following 3-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol. 2003;21:4568-4571.
36. Roach M, Lu J, Pilepich MV, et al. Predicting long term survival, and the need for hormonal therapy: a meta-analysis of RTOG Prostate Cancer Trials. Int J Radiat Oncol Biol Phys. 2000;47:617-627.
37. Roach M 3rd, Weinberg V, McLaughlin PW, Grossfeld G, Sandler HM. Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate. Urology. 2003;61:730-735.
38. Roach M III, Weinberg V, Sandler H, Thompson I. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score? Cancer. 2007;109:213-220.
39. Roach M, Moughan J, Movsas B, et al. Sociodemographic predictors of biochemical failure and survival among high risk patients treated on Radiation Therapy Oncology Group (RTOG) Prostate Cancer Trials: a meta-analysis. Int J Radiat Oncol Biol Phys. 2006;66:S204-S204.